A positive association between BRCA2 p.K3326* mutation and the risk of developing pancreatic cancer has been reported among both familial (8/144 cases versus 3/250 controls, OR = 4.84, 95% CI = 1.27–18.55) and sporadic (69/2,835 cases versus 73/5,446 controls, OR = 1.78, 95% CI = 1.26–2.52) pancreatic ductal adenocarcinomas [28,38]. This evidence concerns the gene BRCA2 and pancreatic neoplasm.